

**MSHO** 

**UPDATE IN**

**HEMATOLOGY & ONCOLOGY**

**2024**



**SEPTEMBER 28**

**Grand Traverse Resort**

## PLANNING COMMITTEE

### **Daniel Isaac, DO**

Course Director  
Michigan State University, KCI McLaren

### **Katie West, MSN, RN**

CME Specialist  
Munson Healthcare

### **Jerome Winegarden, MD**

MSHO President  
Trinity Health - IHA Hematology and  
Oncology Consultants

### **Mary Kay Makarewicz**

Executive Director  
Michigan Society of  
Hematology & Oncology

### **Zachary Hector-Word, MD**

MSHO Education Committee Member  
Cowell Family Cancer Center

## FACULTY

### **Anthony Shields, MD, Ph.D**

Professor  
WSU School of Medicine  
Associate Center Director for  
Clinical Research  
Hematology/Oncology  
Karmanos Cancer Institute

### **Seema Bhat, MD**

Associate Professor  
The Ohio State University  
James Comprehensive Cancer Ctr  
Division of Hematology  
Department of Internal Medicine

### **Yasmin Karimi, MD**

Clinical Assistant Professor  
Division of Hematology/Oncology  
University of Michigan

### **Zachery Reichert, MD**

Clinical Associate Professor  
of Internal Medicine  
Division of Hematology/Oncology  
Department of Urology  
University of Michigan

# AGENDA

- 6:30 am **BREAKFAST/REGISTRATION**
- 7:20 am **Opening Comments**  
Daniel Isaac, DO  
*Michigan State University*
- 7:30 am **Evolving Landscape in Management of CLL**  
Seema Bhat, MD  
*The Ohio State University*  
*Comprehensive Cancer Center*
- 8:25 am **Treatment Landscape for Metastatic  
Castrate-Resistant Prostate Cancer**  
Zachery Reichert, MD  
*University of Michigan*
- 9:20 am **Poster Presentations**
- 9:40 am **BREAK and Floor Poster Presentations**
- 10:00 am **Multi-Disciplinary Management of Colorectal  
Cancer- Managing Complex Cases and Integrating  
Blood Based Molecular Monitoring**  
Anthony Shields, MD, Ph.D  
*Karmanos Cancer Institute*
- 10:55 am **Emerging Treatments for Hodgkin Lymphoma**  
Yasmin Karimi, MD  
*University of Michigan*
- 11:50 pm **COURSE ADJOURNS**

# PROGRAM DETAILS

## PROGRAM OBJECTIVES

At the conclusion of the activity, each learner will be able to:

- 1 Apply the latest evidence to manage patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- 1 Understand which molecular alterations provide sensitivity to PARP inhibition and which do not within PROFOUND study leading to approval for olaparib
- 1 Understand the indications and utility of using ctDNA in colon cancer management
- 1 Select appropriate frontline treatment in patients with high risk Hodgkin lymphoma

## TARGET AUDIENCE

This program will be of interest to oncologists, hematologists, radiation oncologists, nurses, advanced practice providers, and other healthcare professionals who deliver care to cancer patients.

## PROGRAM GOAL

MSHO's goal is to provide our learners with education that is evidence-based and up to date. It will provide best practice guidelines and review recent peer-reviewed published data, free from commercial bias, to facilitate learner's development and implementation of standards of care as well as to close gaps in their professional practice.

## DISCLOSURE STATEMENT

In accordance with the ACCME and Michigan State Medical Society Standards of Commercial Support, Munson Medical Center will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control the content of this CME activity.

Applicable individual faculty and planning committee disclosures will be made prior to each presentation and provided in written material.

# CONTINUING EDUCATION

## **MITIGATION OF RELEVANT FINANCIAL RELATIONSHIPS**

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Munson Healthcare will implement mechanisms to identify and mitigate relevant financial relationships with ineligible companies for all individuals in a position to control content of this activity.

Applicable individual faculty and planning committee disclosures will be made prior to each presentation and provided in written material.

## **ACCREDITATION & CREDIT DESIGNATION STATEMENT**

This activity has been planned and implemented in accordance with the Accreditation Elements and Policies of the Michigan State Medical Society through the joint sponsorship of Munson Healthcare and the Michigan Society of Hematology and Oncology. Munson Healthcare is accredited by the Michigan State Medical Society to provide continuing medical education for physicians.

Munson Healthcare designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **RECOGNITION STATEMENT**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

# REGISTRATION DETAILS

## REGISTRATION

This meeting is funded by the Michigan Society of Hematology and Oncology Foundation. There is no fee for MSHO members to attend as long as registration is received by September 18.

To register [CLICK HERE](#)

## ACCOMMODATIONS

You must be registered to reserve a room. A link will be provided in your conference registration confirmation.

## LOCATION

Grand Traverse Resort  
100 Grand Traverse Village Blvd.  
Acme, MI 49610

## REGISTRATION DEADLINE SEPTEMBER 18, 2024

For more information, contact  
MSHO at [meetings@msho.org](mailto:meetings@msho.org) or 248-385-5464.